The thoracic vascular stent grafts market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of USD 278.9 million by 2033 while the market is likely to reach a value of USD 199.3 million in 2023.
Thoracic vascular stent grafts, also known as thoracic, vascular aneurysm repair. It is a surgical procedure. The demand for the same spike is carried out as an alternative to conventional surgery for the repair of the aortic aneurysm.
Thoracic aneurysm is a bulge in the major artery from the heart which dilates the diameter of the aorta by greater than 150%. This may lead to rupturing or tearing and subsequent internal bleeding, and this is when these grafts come to the fore.
Thoracic vascular stent grafting is a new form of treatment in the vascular stent grafts industry showing promising results. The thoracic vascular stent grafts market growth is fostered by the FDA approval of the thoracic vascular stent grafts in 2005 for descending thoracic aortic aneurysm.
| Attribute | Details |
|---|---|
| Thoracic Vascular Stent Grafts Market CAGR (2023 to 2033) | 3.4% |
| Thoracic Vascular Stent Grafts Market Size (2023) | USD 199.3 million |
| Thoracic Vascular Stent Grafts Market Size (2033) | USD 278.9 million |
There are many different types of stent grafts available in the market, which differ in their insertion procedure and access to the blood vessel. Further, increasing prevalence has been observed in the thoracic aortic aneurysm condition, thus representing a huge opportunity for the market players to launch innovative as well as cost-effective products.
An estimated 21,000 individuals got affected every year in the United States and a prevalence of 10.4 per 10,000 persons has been observed in the United Kingdom. This represents a huge demand for thoracic vascular stent grafts during the forecast period. Moreover, the strict regulatory conditions regarding stent grafts help in keeping the record of several implants in different regions.
Several players in the market are focusing on key emerging markets for huge growth potential and increased distribution channels in these regions. Moreover, the market growth is further facilitated by the fact that thoracic vascular stent grafts represent the only option for elderly patients who cannot withstand the traditional surgery procedure.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Government funding for the development of cost effective healthcare solutions and increase in improvement in diagnostic services are likely to propel the sales of thoracic vascular stent grafts.
Rise in geriatric population in tandem with increasing lifestyle related disorders is expected to boost the demand for these stent grafts. Moreover, the preference of minimal invasive procedures over the conventional surgery owing to less pain, less hospitals stay, less blood loss and low risk of death also supports the market growth.
Growing number of commercially available different types of thoracic vascular stent graft designs also expands the thoracic vascular stent grafts market size. However, poor access to diagnosis in low income countries, lack of trained personnel, and lack of evidence in long term results limits the market growth for the global market of thoracic vascular stent grafts.
| Countries | Revenue Share % (2022) |
|---|---|
| The United States | 34.0% |
| Germany | 5.7% |
| Japan | 4.1% |
| North America | 36.7% |
| Europe | 28.3% |
| Countries | CAGR % (2023 to 2033) |
|---|---|
| China | 4.1% |
| India | 3.5% |
| The United Kingdom | 2.6% |
| Australia | 2.8% |
Government funding for the development of cost-effective healthcare solutions and increased improvement in diagnostic services are likely to propel the sales of thoracic vascular stent grafts. North America held a market share of 36.7% in 2022.
A rise in the geriatric population in tandem with increasing lifestyle-related disorders is expected to boost the demand for stent grafts. Further, the preference for minimally invasive procedures over conventional surgery owing to less pain, a few hospitals stays; less blood loss and low risk of death also support the market growth.
A growing number of commercially available different types of thoracic vascular stent graft designs also expand the thoracic vascular stent grafts market size. However, poor access to diagnosis in low-income countries, lack of trained personnel, and lack of evidence in long-term results limit the market growth for the global market of thoracic vascular stent grafts.
This is followed by the Western Europe region, with EU5 leading the market share as per the current sales trend for these devices, contributing to the region’s thoracic vascular stent grafts market share of 28.3% in 2022.
Technical breakthroughs have occurred on account of the significant increase in the number of conventional graft failures. Medtronic, for example, gained CE Mark for their Endurant II/IIs stent graft system for the treatment of abdominal aortic aneurysms, advancing the market in the region.
| Category | By Product Type |
|---|---|
| Leading Segment | Metal Thoracic Vascular Stent Graft |
| Market Share% (2022) | 62.1% |
| Category | By End Use type |
|---|---|
| Leading Segment | Hospitals |
| Market Share% (2022) | 77.2% |
Based on the product type, the metal segment leads the market as it held a market share of 62.1% in 2022. Based on the end use type, the hospitals segment runs forward by holding a market share of 77.2% in 2022.
Numerous thoracic vascular stent graft start-ups are coming up. One of the significant ones is Aortica, a Seattle-area biotech. It is developing a tailored approach to treating aortic aneurysms, specifically complicated abdominal aortic aneurysms, which are difficult to cure.
The start-up has secured just over USD 1 million of a USD 4 million round of insider funding to further develop the treatment Aortica. CEO and founder Thomas Douthitt told GeekWire that the company has pledged to finish the entire USD 4 million round.
Dr Benjamin Starnes, a prominent surgeon who oversees vascular surgery at the University of Washington Medical Center and Harborview Medical Center in Seattle, created Aortica in 2014. He is now heading clinical trials of Aortica's technology at Harborview.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Relentless competition is experienced by top manufacturers owing to the emergence of start-up companies in this sector, as well as the increasing sales of 3D TVS packages.
Recent Developments:
The market held a value of USD 194 million in 2022.
Metal thoracic vascular stent grafts segment dominates the market.
Focus on innovative and cost-effective products for thoracic vascular stent grafts.
China, India, Malaysia, Singapore, and Australia are key regions.
Healthcare and hospitals are the key consumers.
| Estimated Size, 2025 | USD 1,408.7 million |
|---|---|
| Projected Size, 2035 | USD 2,338.8 million |
| Value-based CAGR (2025 to 2035) | 5.2% |
| Market Size in 2023 | USD 2.5 billion |
|---|---|
| Projected Market Value in 2033 | USD 4.2 billion |
| Value-based CAGR (2023 to 2033) | 5% |
Explore Therapeutic Device Insights
View Reports
Thoracic Vascular Stent Grafts Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
